DSM-Firmenich stock supported by ongoing share buyback program
Published on 08/19/2026 at 19:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DSM-Firmenich (CH1216478797) is continuing to support its capital structure with an ongoing share repurchase program, as the company reported new buybacks executed between August 10, 2026 and August 14, 2026 at an average price of EUR 92.13 per share.
Share buyback activity in August 2026
According to a recent company communication the latest weekly update on the share repurchase program covers the period from August 10, 2026 to August 14, 2026. In that five-day window, DSM-Firmenich bought back a total of 139,500 shares on the market. The average purchase price in this period was EUR 92.13 per share, corresponding to a total consideration of EUR 12.9 million for this specific tranche of the program.
The company states that the repurchased shares will be used to cover employee share plans and to reduce capital. Compared with earlier phases of capital return programs in the chemicals and ingredients sector, a buyback of 139,500 shares in one week at an average price above EUR 90 highlights the scale of DSM-Firmenich's current effort to manage its equity base using on-market purchases.
Capital structure and investor implications
The ongoing repurchase program indicates that DSM-Firmenich is prepared to commit meaningful cash resources to buying its own stock at prices around the low EUR 90s, at least over the week ended August 14, 2026. For investors, a key comparison point is the total cost of EUR 12.9 million for that week against the number of shares bought, which underscores that each tranche of the program involves a significant capital outlay.
While the latest weekly update focuses on executed trades rather than guidance or earnings, the combination of a defined number of shares (139,500) and a clear average price (EUR 92.13) provides a transparent reference for how the company is implementing its capital return strategy in August 2026. If the prevailing market price for DSM-Firmenich stock stays close to this level, the repurchase program could gradually reduce the free float, which over time affects metrics such as earnings per share even before underlying operating results change.
Nutrition and perfumery portfolio
DSM-Firmenich's repurchase activity runs alongside its strategic positioning as a combined nutrition, health and beauty company. The group brings together long-established strengths in vitamins and nutritional ingredients with expertise in flavors, fragrances and perfumery. A representative example from its portfolio is its tailored solutions for food and beverage manufacturers, where DSM-Firmenich supplies flavor and fragrance compositions designed to provide consistent taste profiles in soft drinks and dairy alternatives.
These product solutions typically integrate functional ingredients with sensory design in order to meet customer requirements for taste, stability and regulatory compliance. This allows DSM-Firmenich to leverage its research and development capabilities across both the nutrition and perfumery sides of its business in support of branded consumer goods companies.
DSM-Firmenich stock and recent buyback pricing
DSM-Firmenich shares are listed in Europe, and the company's recent disclosure that it bought 139,500 shares in the market between August 10, 2026 and August 14, 2026 at an average price of EUR 92.13 per share gives a clear indication of the price level at which management has been willing to repurchase stock. The total cash outlay of EUR 12.9 million for this tranche underscores the company's commitment to its repurchase program as of mid-August 2026.
Fact box
Company: DSM-Firmenich AG
ISIN: CH1216478797
